We report two cases of human parvovirus B19 infection as a rare but anticipated complication shortly after allogeneic peripheral blood stem cell transplantation (PBSCT), which were self-limiting in their course.
The first patient was a 48-year-old female treated for secondary acute myeloid leukaemia (AML) FAB M2 following chemotherapy for breast cancer 7 years ago. She received a PBSCT in second complete remission, from a matched unrelated donor, after conditioning with 2 Gy total-body irradiation, 120 mg/m 2 fludarabine, 60 mg/kg cyclophosphamide and 30 mg/kg antithymocyte globulin. Immunosuppressive therapy was initiated with cyclosporine and mycofenolate. One day before transplantation, the patient presented with sudden skin erythema, which soon resolved without any treatment. On day 10 after PBSCT, she developed an erythematous itchy eruption of the skin on both arms and the neck line, initially reminiscent of acute graft-versus-host disease (aGvHD), but subsequently very inconsistent in its appearance in that it migrated from the neck line to the abdomen and back and finally to both legs. This lasted for a period of 14 days. Our differential diagnosis included early acute cutaneous GvHD, viral erythema and drug-induced erythema. The latter seemed unlikely as no new drug had been administered. To clarify the diagnosis a skin biopsy was taken. Surprisingly, this turned out to be positive for parvovirus B19 upon polymerase chain reaction (PCR), as was a bone marrow aspirate (700 copies/ml) taken at the same time. PCR from skin samples were not analysed quantitatively. Histology did not show any signs suggestive of GvHD but a nonspecific pattern of inflammation with distinct signs of cytotoxicity, as is frequently seen in skin lesions because of viral infections. Blood was positive for parvovirus B19 immunoglobin G (IgG) before transplantation. Findings were negative for parvovirus B19 IgM before, during and after the infection. Parvovirus B19 PCR in peripheral blood was also negative during and after the infection.
The second patient was a 49-year-old female with AML FAB M1 who received a PBSCT from a matched unrelated donor in second complete remission. She received the same conditioning regimen and immunosuppression as the first patient. On day 7 after PBSCT, the patient developed transient erythema of the skin, extending to laterally on both upper arms and the gluteal region, typical sites of parvovirus B19 skin manifestations in adults, which disappeared completely after 6 days. PCR for parvovirus B19 was positive from a skin biopsy and bone marrow. Copy numbers were few compared to those detectable from blood samples during primary infection in immunocompetent individuals, but parvovirus B19 is anyway seldom detectable in bone marrow specimens. It was not possible to analyse PCR quantitatively from skin biopsy samples owing to different preparation methods in tissues and blood. Because of the specific reaction upon which the PCR is based, direct evidence of parvovirus DNA by PCR from skin and bone marrow is considered to be significant despite low counts. Again, histology showed no signs of aGvHD or drug-induced erythema but a nonspecific abnormality consistent with subacute eczema. Blood results were similar to those in patient 1.
On day 24, the patient developed a second erythematous eruption, this time spreading over the entire skin of the extremities and persisting for 10 days. A second biopsy of the skin was again positive for parvovirus B19 on PCR. Laboratory findings from donors concerning parvovirus B19 IgM, IgG or PCR at the time of PBSC donation are not part of the routine checkup and were therefore not analysed.
Parvovirus B19 infection usually produces a transient IgM-B19-specific response followed by an IgG response that generally confers immunity. The missing IgM response can be explained by the inability of patients to produce neutralizing antibodies. A retrospective study of parvovirus B19 antibody titres 2 to 3 years after bone marrow transplantation showed persisting IgG, suggesting that persistence of B19 antibody depends on prior recipient, but not donor, immunity. 1 Infection with parvovirus B19 has many clinical manifestations, including erythema infectiosum ('fifth disease'), arthritis and vasculitis, severe anaemia, and fetal death. The virus has a high affinity for human bone marrow and replicates only in erythroid progenitor cells. 2 Owing to the preparative regimens, PBSCT consistently results in severe immunodeficiency. It is known that human parvovirus B19 can persist in red blood cell precursors in the bone marrow of immunocompromised patients. An infection can cause severe complications including chronic bone marrow failure or pure red cell aplasia because of the inability of patients to produce neutralizing antibodies against the virus.
3 The major route of transmission of parvovirus B19 is inhalation of respiratory droplets from infected people. Both of these patients were treated in special air-filter rooms designed to create a pathogen-reduced environment and no clinical infections were in family members or hospital staff. There is evidence for parvovirus B19 transmission via blood products, PBSC or bone marrow. 4, 5 Patients required erythrocyte infusions during conditioning before trans-plantation. Parvovirus B19 is known to be a frequent contaminant of blood products, 6 but as parvovirus B19 screening is not part of the routine control of blood products in Germany it was not analysed, and so infection via this route cannot be excluded. Patient 1 developed skin erythema a day before transplantation concomitant with conditioning. Hence, the most likely route seems to be endogenous reinfection with parvovirus B19 during immunosuppressive conditioning and further immunosuppression. This concept is supported by several reports both in PBSCT and in solid organ transplantation. 7 There was no increase in requirement for red blood cell units (RBCU) or platelet transfusions in either case (seven RBCU and four TC in patient 1 and four RBCU and six TC in patient 2 with platelet engraftment on days þ 14 and þ 10, respectively) during the first 40 days compared to other patients who received the same conditioning regimen, and thus the explanation might be decelerated regeneration of hematopoiesis after immunosuppressive conditioning rather than anaemia caused by parvovirus B19. Other reports refer to late severe anaemia after PBSCT caused by parvovirus B19 infection. 8 There was no deceleration in leukocyte engraftment which was achieved on days þ 30 and þ 23, respectively. In both patients, complete donor haematopoiesis was detected in the bone marrow at day þ 30. Intravenous Ig treatment was not required because of the self-limiting nature of the erythema in both cases. However, this represents the only therapy for parvovirus B19-induced severe infections to date. 9 In conclusion, our report shows that parvovirus B19-induces erythematous infection in immuncompromised patients early after PBSC transplantation and should be considered in the differential diagnosis of acute GvHD of the skin. It highlights the importance of excluding the possibility of a viral infection before initiating treatment for acute GvHD. Furthermore, parvovirus B19 infection should be considered in cases of late anaemia after PBSC or bone marrow transplantation, occurring in patients known to be seropositive for parvovirus B19 IgG.
